Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.

@article{Pan2014ClinicalPO,
  title={Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.},
  author={Wei-Jian Pan and Kathleen K{\"o}ck and William A. Rees and Barbara A. Sullivan and Christine M Evangelista and Mark Yen and J M Andrews and Graham L Radford-Smith and Peter J Prince and Kaz O Reynhardt and David R Doherty and Sonal K Patel and Christine D Krill and Kefei Zhou and Jing Shen and Lynn M Smith and Jason M. Gow and Jonathan Y-L Lee and Anthony M Treacy and Zhigang Yu and Virginia M Platt and Dominic C. Borie},
  journal={British journal of clinical pharmacology},
  year={2014},
  volume={78 6},
  pages={1315-33}
}
AIMS AMG 181 pharmacokinetics/pharmacodynamics (PK/PD), safety, tolerability and effects after single subcutaneous (s.c.) or intravenous (i.v.) administration were evaluated in a randomized, double-blind, placebo-controlled study. METHODS Healthy male subjects (n= 68) received a single dose of AMG 181 or placebo at 0.7, 2.1, 7, 21, 70 mg s.c. (or i.v.), 210 mg s.c. (or i.v.), 420 mg i.v. or placebo. Four ulcerative colitis (UC) subjects (n= 4, male : female 2:2) received 210 mg AMG 181 or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS